GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds

With disease-modifying compounds targeting alpha-synuclein available in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies is a much-needed prerequisite. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically a...

Descripción completa

Detalles Bibliográficos
Autor principal: Brockmann, Kathrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545538/
https://www.ncbi.nlm.nih.gov/pubmed/33102473
http://dx.doi.org/10.3389/fcell.2020.562522
_version_ 1783592047610953728
author Brockmann, Kathrin
author_facet Brockmann, Kathrin
author_sort Brockmann, Kathrin
collection PubMed
description With disease-modifying compounds targeting alpha-synuclein available in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies is a much-needed prerequisite. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically associated with the alpha-synucleinopathies: Parkinson’s disease and dementia with Lewy bodies.
format Online
Article
Text
id pubmed-7545538
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75455382020-10-22 GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds Brockmann, Kathrin Front Cell Dev Biol Cell and Developmental Biology With disease-modifying compounds targeting alpha-synuclein available in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies is a much-needed prerequisite. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically associated with the alpha-synucleinopathies: Parkinson’s disease and dementia with Lewy bodies. Frontiers Media S.A. 2020-09-25 /pmc/articles/PMC7545538/ /pubmed/33102473 http://dx.doi.org/10.3389/fcell.2020.562522 Text en Copyright © 2020 Brockmann. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Brockmann, Kathrin
GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
title GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
title_full GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
title_fullStr GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
title_full_unstemmed GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
title_short GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
title_sort gba-associated synucleinopathies: prime candidates for alpha-synuclein targeting compounds
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545538/
https://www.ncbi.nlm.nih.gov/pubmed/33102473
http://dx.doi.org/10.3389/fcell.2020.562522
work_keys_str_mv AT brockmannkathrin gbaassociatedsynucleinopathiesprimecandidatesforalphasynucleintargetingcompounds

Ejemplares similares